Business Trends
Novo Nordisk’s Pipeline Plan Fails to Ease Patent-Cliff Concerns as Shares Slide
Novo Nordisk shares fell about 8% after its capital markets day left investors looking for more clarity on growth beyond semaglutide. The company outlined a $23 billion pipeline target and at least five potential multi-blockbusters, but near-term questions remain.